Delving into the Latest Updates on CD133+ autologous bone marrow stem cell(Miltenyi Biotec B.V. & Co. KG) with Synapse

Overview

Basic Info

Drug Type

Stem cell therapy

Synonyms-

Target-

Mechanism

Stem cell replacements

Therapeutic Areas

NeoplasmsCardiovascular DiseasesNervous System Diseases+ [1]

Active Indication-

Inactive Indication

Angina PectorisCardiomyopathiesCoronary Artery Disease+ [8]

Originator Organization

Miltenyi Biotec, Inc.

Active Organization-

Inactive Organization

Miltenyi Biomedicine GmbHStartup

Miltenyi GmbHMiltenyi Biotec, Inc.

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

Regulation-

Login to view timeline

In spite of the fact that the post-myocardial infarction survival rate has improved with recent medical advances, reduced heart function attributed to irreversible loss of viable cardiomyocytes is still a major clinical problem.
The aim of the current study is to determine whether intramyocardial injection of autologous CD133+ bone marrow stem cells yields a functional benefit in addition to coronary artery bypass graft (CABG) surgery in patients with chronic ischemic coronary artery disease.

Start Date01 Jul 2009

Sponsor / Collaborator

Miltenyi GmbH

[+1]

100 Clinical Results associated with CD133+ autologous bone marrow stem cell(Miltenyi Biotec B.V. & Co. KG)

Login to view more data

100 Translational Medicine associated with CD133+ autologous bone marrow stem cell(Miltenyi Biotec B.V. & Co. KG)

Login to view more data

100 Patents (Medical) associated with CD133+ autologous bone marrow stem cell(Miltenyi Biotec B.V. & Co. KG)

Login to view more data

100 Deals associated with CD133+ autologous bone marrow stem cell(Miltenyi Biotec B.V. & Co. KG)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Coronary Disease	Phase 3	DE	Miltenyi Biotec, Inc.	15 Jul 2020
Diabetes Mellitus, Type 2	Phase 3	US	Miltenyi Biotec, Inc.	31 Jan 2010
Myocardial Infarction	Phase 3	DE	Miltenyi GmbH	31 Jul 2009
Neoplasms	Phase 3	DE	Miltenyi GmbH	31 Jul 2009
Ventricular Arrhythmia	Phase 3	DE	Miltenyi GmbH	31 Jul 2009
Angina Pectoris	Phase 3	DE	Miltenyi Biomedicine GmbHStartup	01 Apr 2007
Coronary Artery Disease	Phase 3	DE	Miltenyi Biomedicine GmbHStartup	01 Apr 2007
Coronary Artery Disease	Phase 3	DE	Miltenyi Biomedicine GmbHStartup	01 Apr 2007
Heart Failure	Phase 3	DE	Miltenyi Biomedicine GmbHStartup	01 Apr 2007
Old myocardial infarction	Phase 3	DE	Miltenyi Biomedicine GmbHStartup	01 Apr 2007